We have previously shown that intranasal infection of mice with mouse hepatitis virus (MHV) strain UAB (MHV-UAB) increases their resistance to Salmonella typhimurium injected intravenously 6 days later. To study how salmonella resistance was induced, BALB/cAnNCr mice were infected with salmonella strains carrying specific genetic alterations. One set of studies compared the effect of MHV infection on subsequent salmonella infections with AroA-(avirulent) and Aro+ (virulent) salmonellae. Unlike its effect on Aro+ salmonellae, MHV failed to reduce the number of AroA-salmonellae recovered from mice. Because AroA-S. typhimurium shows almost no growth in vivo, this failure indicated that the effect of MHV on salmonella resistance required growth of the infecting salmonellae. In other studies, the effect of MHV infection on both growth and killing were monitored simultaneously in mice with growing salmonellae carrying a single copy of the temperature-sensitive pHSG422 plasmid, which is unable to replicate in vivo. MHV infection reduced salmonella growth but caused no increase in salmonella killing. MHV infection of mice given wild-type salmonellae also resulted in no increase in salmonella killing 4 h after salmonella challenge. These studies demonstrate that MHV-UAB infection increases host resistance to salmonellae by enhancing suppression of bacterial growth instead of by increasing the amount of salmonella killing.
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Most reported interactions between viral and bacterial pathogens result in increased susceptibility to the bacterial pathogen (20) . However, we found that if mice are infected intravenously with Salmonella typhimurium 6 days after intranasal inoculation with mouse hepatitis virus (MHV) strain UAB (MHV-UAB), significantly fewer salmonellae were found in their spleens and livers 3, 4, and 5 days after salmonella infection than were found in control mice which did not receive MHV (14). MHV-UAB infection increased the host resistance of BALB/cAnNCr mice to doses of 102 to 105 CFU of virulent S. typhimurium, but it was not clear if MHV infection induced primarily bactericidal (killing) or bacteriostatic (growth-suppressing) mechanisms in the host. Differentiating between killing and growth suppression is important, because different intracellular mechanisms of resistance are probably involved in these two effects. For instance, generation of oxygen radicals and the action of basic proteins and lysosomal enzymes are thought to mediate intracellular killing by phagocytes (11, 15, 21) , whereas nutrient sequestration has been suggested as a mechanism of intracellular growth suppression (2, 5, 16) .
In this report, we present studies undertaken to determine the effect of MHV on salmonella resistance in vivo. One approach was to determine the number of salmonellae surviving in the mice shortly after completion of blood clearance of intravenously injected salmonellae. A second approach was to infect mice with AroA-salmonellae that cannot grow in vivo so that cumulative host killing 4 days after salmonella challenge could be evaluated without the complication of ongoing bacterial growth. The third approach was to infect mice with salmonellae carrying a single copy of the pHSG422 temperature-sensitive plasmid, which confers kanamycin resistance. The plasmid does not significantly replicate in vivo during the first 48 h after infection (2), so by comparing the initial number of injected salmonellae with and without the plasmid just prior to and 1 or 2 days after infection, a determination of both salmonella growth and killing in vivo could be made.
Our findings indicate that MHV-infected mice kill slightly fewer salmonellae during blood clearance but that this effect is more than overcome by salmonella growth suppression, resulting in the recovery of significantly fewer salmonellae from MHV-infected mice as early as 2 days after salmonella challenge.
MATERIALS AND METHODS
Mice. Weanling female BALB/cAnNCr mice (National Cancer Institute breeding facility, Frederick, Md.) were received in filter-ported crates and maintained in microisolator cages (Lab Products, Aberdeen, Md.) with sterile food, water, and bedding. Sera from mice were periodically screened for antibodies to MHV, Sendai virus, lymphocytic choriomeningitis virus, mouse rotavirus, pneumonia virus of mice, reovirus 3, Theiler's GD-VII virus, minute virus of mice, K virus, mouse poxvirus, and Mycoplasma pulmonis (Charles River Professional Services, Wilmington, Mass.) to verify that mice were free of these pathogens before experimentation and that cross-contamination between MHVinfected and control groups did not occur. Mice were used in experiments at 9 to 16 weeks of age.
Virus. Frozen aliquots (-70°C) of fourth-passage MHV-UAB were thawed just prior to use in all experiments. This mouse coronavirus is a field strain whose isolation has been previously described (9) . Experimental mice were anesthetized with an intraperitoneal injection of ketamine (Aveco Co., Inc., Fort Dodge, Iowa) and xylazine (Haver-Lockhardt, Minneapolis, Minn.) and then were inoculated intranasally with 100 PFU of virus 6 days before challenge with salmonellae in 200 ,ul of saline via a lateral tail vein. Control mice received an equal volume of sterile medium intranasally in place of MHV. S. typhimurium strains. Pertinent information about the salmonella strains used is given in Table 1 . Virulence was determined by recording the daily deaths of mice for 20 days after intravenous injections of mice with graded (10x) doses of salmonellae. The 50% lethal doses were determined by extrapolating between those consecutive doses of salmonellae that caused mortality higher and lower than 50% during the 20-day period. For the 4-h organ distribution studies, strain SR-11 was used. Frozen aliquots (-70°C) of bacteria from late-log-phase broth cultures were thawed and appropriately diluted in sterile saline just prior to injection via lateral tail vein. In the AroA-salmonella studies, AroAstrain WB247 and virulent Aro+ strain WB248 were used. Strain WB244, bearing the temperature-sensitive plasmid pHSG422, which confers kanamycin resistance, was prepared for injection as previously described (2) . Briefly, WB244 was maintained in Luria broth (Difco, Detroit, Mich.) containing kanamycin at 30°C until stationary phase, when the plasmid copy number peaks at 8 to 10 per cell. To obtain an inoculum containing less than one plasmid per salmonella, a portion of this culture was seeded into fresh medium without kanamycin and incubated for about 2.5 h at the nonpermissive temperature of 37°C so that the salmonellae could replicate but the plasmids could not. At the end of the incubation period, 50 to 80% of the salmonellae contained a single copy of the plasmid. To verify that the salmonellae contained only one plasmid each, a portion of the inoculum culture was plated on nutrient agar (BBL Microbiology Systems, Cockeysville, Md.) with kanamycin to determine the number of plasmid-bearing salmonellae; the total number of plasmids was determined by incubating a portion of the inoculum at 42°C to allow complete segregation of single plasmids into individual salmonellae. From this information, the copy number (plasmids per plasmid-bearing salmonella) of 1 (or slightly less because of experimental error) was verified. After injection, the mice were maintained at 32°C in 50% humidity to help prevent plasmid replication.
Determination of salmonella counts in organs and blood. The numbers of salmonella CFU in spleens, livers, lungs, and kidneys were determined individually. Each organ was homogenized in cold saline with a Stomacher tissue homogenizer (Tekmar Co., Cincinnati, Ohio), further diluted in cold saline, and then plated on nutrient agar. With the exception of the plates with kanamycin that were used to detect salmonellae bearing the pHSG422 plasmid (kept at 30°C), plates were incubated at 37°C. The number of salmonellae in blood was determined by plating neat blood and saline dilutions thereof.
Statistical analysis. The number of salmonellae recovered from organs was expressed as a base 10 logarithm. Data were analyzed by the multifactorial analysis of variance technique. Differences between group geometric means were considered significantly different when P was <0.05. In the event of significant factor interactions (P < 0.05), differences between individual means were tested for significance by Scheffe's test (6) . Experiments were performed independently at least twice to verify results. Each experimental group contained six mice. RESULTS MHV-UAB infection does not enhance host killing of salmonellae in the initial clearance phase immediately following salmonella infection. During the first few hours immediately following intravenous salmonella injection, virtually all salmonellae are cleared from the blood and about 90% of them are killed (10, 19) . To determine if MHV-infected mice had fewer salmonellae in their spleens and livers (indicative of increased host killing during this important early clearance phase), the number of salmonellae in those organs was determined 4 h after mice were injected with 5 x 105 CFU of strain SR-11 salmonellae. Slightly more salmonellae were recovered from the livers and spleens of MHV-infected mice than from controls receiving only salmonellae ( Table 2 ). The number of salmonellae in the kidneys, lungs, and blood was also determined to see if MHV-UAB infection was altering the distribution of salmonellae in the mice. The kidney, blood, and lung contained less than 7% of the salmonellae recovered from either normal or MHV-infected mice ( Table  2 ). The twofold average increase in salmonella recovery from the liver and spleen was not associated with a detectable decrease in salmonella recovery from the kidney, blood, or lung. These results make it clear that MHV-UAB infection does not increase salmonella killing in the spleen or liver during the first 4 h following salmonella injection and may actually slightly decrease salmonella killing. Our finding that the great majority of salmonellae that survive are found in the liver and spleen was consistent with previous reports (3, 18).
Use of AroA-salmonellae to assess cumulative host killing. We used salmonellae with the AroA-mutation to measure As expected from previous studies (14), MHV-infected mice had significantly fewer Aro+ salmonellae in their spleens and livers than control mice at both the 104 and i0' doses (Table 3 ). In contrast, there was no difference in the numbers of salmonellae recovered from the spleens of MHV-infected and control mice given either AroA-dose, and the livers of MHV-infected mice had more AroAsalmonellae at both doses than did controls.
If the decreased recovery of Aro+ salmonella from MHVinfected mice was due to increased salmonella killing, we should have found fewer AroA-salmonellae in MHVinfected animals. Instead, we found about the same (spleen) or more (liver) AroA-salmonellae, which indicates that active salmonella growth must be present for MHV to induce resistance to salmonellae.
Use of salmonellae bearing the pHSG422 temperaturesensitive plasmid to assess growth and killing in vivo. The failure of MHV-UAB infection to increase the resistance of mice to AroA-salmonellae strongly suggested that MHV-UAB infection increases resistance to salmonellae by suppressing growth of this organism. To test this possibility with growing salmonellae, we utilized salmonellae carrying the temperature-sensitive pHSG422 plasmid. Previous studies have shown that within the first 2 days after infection of mice, so little replication of the plasmid is observed that the plasmid may be considered nonreplicative in vivo (2) . During this 2-day period, the plasmid provides a good marker for assessing in vivo growth and killing of salmonellae simultaneously (2). The slow but cumulative plasmid growth becomes significant after 2 days and precludes use of the plasmid as a stable marker to evaluate growth and killing at later times.
Mice were given 100 PFU of MHV or sterile medium (controls), and 6 days later, all mice were injected with 2 x 105 salmonellae, 75% of which were plasmid bearing, with a calculated pHSG422 copy number of 0.8. Similar numbers of plasmid-containing salmonellae were observed at both 24 and 48 h, regardless of whether the mice had been previously infected with MHV (Table 4 ). The lack of increased killing at 24 and 48 h in control mice confirmed our earlier finding that there is little if any salmonella killing between 24 and 48 h (2) . The lack of a significant difference in the numbers of plasmid-bearing salmonellae recovered from the MHV-infected and non-MHV-infected (control) mice indicated, as in the AroA-studies described above, that similar percentages of salmonellae were killed regardless of MHV infection.
Although the effect of MHV on salmonella resistance was small at 48 h, we did observe significantly larger numbers of salmonellae in the control mice than in MHV-infected mice, and as expected, a significantly greater percentage of the salmonellae recovered from MHV-infected mice contained the plasmid. The observation that there was less dilution of the plasmid in the salmonellae recovered from MHV-in- b An asterisk denotes an MHV-infected group significantly different from its control group (P < 0.05).
fected mice indicated that there was less salmonella growth in the MHV-infected mice. It was apparent from the results that the lower recovery of total salmonella CFU from MHV-infected mice was the result of salmonella growth suppression.
DISCUSSION
The conclusion that MHV-UAB infection induces resistance to salmonellae by bacteriostatic means is consistent with the results of studies utilizing both AroA-and plasmidbearing salmonellae. The studies using AroA-salmonellae allowed detection of the maximal effect of prior MHV infection on growth because it allowed us to look at a later point in infection than was possible when plasmid-containing salmonellae were used. A difficulty with the AroA-studies was that they did not rule out the possibility that MHV affects growth-dependent killing of salmonellae. However, the results of our studies with growing salmonellae bearing the temperature-sensitive plasmid eliminate this possibility.
In addition to MHV-mediated reduction in salmonella growth rate, MHV infection also resulted in slightly less killing of salmonellae shortly after infection. This was evident from the greater recovery of SR-11 salmonellae from spleens and livers of MHV-infected mice 4 h after salmonella injection and from the greater recovery of AroA-salmonellae from the livers of MHV-infected mice 4 days after salmonella injection. The lack of evidence for an MHVmediated reduction in killing of AroA-salmonellae in the spleen 4 days after challenge may be due to the comparatively small 1.5-fold increase in salmonella recovery from the spleens of MHV-infected mice 4 h after challenge compared with the 3-fold increase observed in the liver (Table 2) . Thus, although the predominant effect of MHV infection was salmonella growth suppression, MHV infection may also slightly reduce salmonella killing during blood clearance.
A trivial explanation for our finding that MHV-infected mice have fewer salmonellae in spleens and livers than controls 2 to 4 days after salmonella injection (14) is that MHV infection is causing a preferential seeding of the injected salmonellae to organs other than the liver or spleen. However, this explanation is incorrect, because 4 h after salmonella injection, MHV-infected mice had slightly more, rather than fewer, salmonellae in their spleens and livers.
It should be emphasized that not all MHV strains would be expected to have the same effects on salmonella resistance under our experimental conditions because numerous MHV strains have been described that have divergent pathogenic properties in mice. As is often the case with more recently isolated field strains, MHV-UAB is weakly pathogenic compared with classical strains such as MHV-2 and MHV-3 (1).
The clinical signs associated with MHV-UAB infection in the BALB/cAnNCr mice used in this study were limited to a slight ruffling of the fur 5 to 7 days after inoculation. In contrast, highly pathogenic MHV-3 killed the same BALB/ cAnNCr mice less than 4 days after inoculation (12) . The weak pathogenicity of MHV-UAB was ideal for our purposes of probing salmonella resistance because the virus was able to induce a significant biological effect (salmonella resistance) with a minimum of host alterations.
Our results suggest that host bacteriostatic mechanisms can be stimulated by exogenous agents to induce significant resistance against salmonellosis in susceptible mice. This finding is consistent with recent findings that the major effect of the Ity locus on resistance to salmonellosis is regulation of salmonella growth (2) . The mechanism(s) by which MHV-UAB infection induces resistance is unknown, but the release of cytokines that trigger bacteriostatic mechanisms in the host following MHV-UAB infection is a likely possibility. In fact, the MHV-UAB used in this work does induce large amounts of type I interferon (13) , which may play a role in the induction of resistance to salmonellosis (7, 8) . Another possibility is that MHV-UAB infection of phagocytic cells intrinsically renders the cells more resistant to salmonella infection. It is hoped that a better understanding of how MHV-UAB induces resistance to salmonellosis will give clues as to how the host resists salmonella infections and how new treatments against systemic salmonellosis can be designed.
